Comparison of reperfusion regimens with or without Tirofiban in ST-elevation acute myocardial infarction

American Journal of Cardiology

Volumn 93, Issue 3, 2004, Pages 280-287

  Martínez Ríos, Marco A ^a   Rosas, Martín ^a   González, Héctor ^a   Peña Duque, Marco A ^a   Martínez Sánchez, Carlos ^a   Gaspar, Jorge ^a   García, Héctor ^a   Gaxiola, Efraín ^a   Delgado, Luis ^a   Carrillo, Jorge ^a   Leyva, José Luis ^a   Lupi, Eulo ^a  

^a INSTITUTO NACIONAL DE CARDIOLOGÍA IGNACIO CHÁVEZ   (Mexico)

Author keywords

[No Author keywords available]

Indexed keywords

ALTEPLASE; DRUG DERIVATIVE; FIBRINOGEN RECEPTOR; FIBRINOLYTIC AGENT; TIROFIBAN; TISSUE PLASMINOGEN ACTIVATOR; TYROSINE;

ACUTE HEART INFARCTION; ADULT; AGED; ANGIOCARDIOGRAPHY; ARTICLE; BLEEDING; BLOOD CLOT LYSIS; BRAIN HEMORRHAGE; CLINICAL FEATURE; CLINICAL TRIAL; COMPARATIVE STUDY; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY BLOOD FLOW; CORONARY STENT; DEATH; DOSE RESPONSE; ELECTROCARDIOGRAPHY; FEMALE; FIBRINOLYTIC THERAPY; FLOW RATE; HAZARD ASSESSMENT; HEART FAILURE; HEART INFARCTION; HEART MUSCLE REPERFUSION; HEART REINFARCTION; HUMAN; INFUSION; LOW DRUG DOSE; LUNG EDEMA; MAJOR CLINICAL STUDY; MALE; METHODOLOGY; MULTICENTER STUDY; MULTIMODALITY CANCER THERAPY; PERCUTANEOUS CORONARY INTERVENTION; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; RADIOGRAPHY; RANDOMIZED CONTROLLED TRIAL; REVASCULARIZATION; ST SEGMENT ELEVATION; STANDARDIZATION; STATISTICAL SIGNIFICANCE; STENT; STROKE; THROMBOCYTOPENIA; TIME; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT OUTCOME;

EID: 10744221332     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2003.10.005     Document Type: Article

References (26)

1. The Thrombolysis in Myocardial Infarction (TIMI) trial phase I findings . N Engl J Med. 312:1985;932-936.
2. Lee K.L., Woodlief L.H., Topol E.J., Weaver W.D., Betriu A., Col J., Simoons M., Aylward P., Van de Werf F., Califf R.M. Predictors of 30-day mortality in the era of reperfusion for acute myocardial infarction results from international trial of 41 021 patients . Circulation. 91:1995;1659-1668.
3. Davies C.H., Ormerod O.J.M. Failed coronary thrombolysis. Lancet. 351:1998;1191-1196.
4. Cannon C.P. Overcoming thrombolytic resistance. Rationale and initial experience combining thrombolytic therapy and glycoprotein IIb/IIIa receptor inhibition for acute myocardial infarction. J Am Coll Cardiol. 34:1999;1395-1402.
5. Schomig A., Kastrati A., Dirschinger J., Mehilli J., Schricke U., Pache J., Martinoff S., Neumann F.J., Schwaiger M. Coronary stenting plus platelet glycoprotein IIb/IIIa blockade compared with tissue plasminogen activator in acute myocardial infarction. N Engl J Med. 343:2000;385-391.
6. Stone G.W., Grines C.L., Cox D.A., Garcia E., Tcheng J.E., Griffin J.J., Guagliumi G., Stuckey T., Turco M., Carroll J.D., Rutherford B.D., Lansky A.J. Comparison of angioplasty with stenting with or without abciximab, in acute myocardial infarction. N Engl J Med. 346:2002;957-966.
7. Topol E.J. Toward a new frontier in myocardial reperfusion therapy. Emerging platelet preeminence. Circulation. 97:1998;211-218.
8. Van de Werf F., Baim D.S. Reperfusion for ST-segment elevation myocardial infarction an overview of current treatment options . Circulation. 105:2002;2813-2816.
9. Keeley E.C., Boura J.A., Grines C.L. Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction a quantitative review of 23 randomized trials . Lancet. 361:2003;13-20.
10. Ohman E.M., Kleiman N.S., Gacioch G., Worley S.J., Navetta F.I., Talley J.D., Anderson H.V., Ellis S.G., Cohen M.D., Spriggs D., et al. Combined accelerated tissue-plasminogen activator and platelet glycoprotein IIb/IIIa integrin receptor blockade with integrilin in acute myocardial infarction results of a randomized, placebo-controlled, dose-ranging trial . Circulation. 95:1997;846-854.
11. Antman E.M., Giugliano R.P., Gibson C.M., McCabe C.H., Coussement P., Kleiman N.S., Vahanian A., Adgey A.A., Menown I., Rupprecht H.J., et al. Abciximab facilitates the rate and extent of thrombolysis. Results of the Thrombolysis in Myocardial Infarction (TIMI) 14 trial. Circulation. 99:1999;2720-2732.
12. de Lemos J.A., Antman E.M., Gibson C.M., McCabe C.H., Giugliano R.P., Murphy S.A., Coulter S.A., Anderson K., Scherer J., Frey M.J., et al. Abciximab improves both epicardial flow and myocardial reperfusion in ST-elevation myocardial infarction. Observations from TIMI 14 trial. Circulation. 101:2000;239-243.
13. Brener S.J., Zeymer U., Adgey A.A., Vrobel T.R., Ellis S.G., Neuhaus K.L., Juran N., Ivanc T.B., Ohman E.M., Strony J., Kitt M., Topol E.J. Eptifibatide and low-dose tissue plasminogen activator in acute myocardial infarction. The Integrilin and Low-dose Thrombolysis in Acute Myocardial Infarction (INTRO AMI) trial. J Am Coll Cardiol. 39:2002;377-386.
14. Boersma E., Harrington R.A., Moliterno D.J., White H., Theroux P., Van de Werf F., de Torbal A., Armstrong P.W., Wallentin L.C., Wilcox R.G., et al. Platelet glycoprotein IIb/IIIa inhibitors in acute coronary sindromes a meta-analysis of all major randomised clinical trials . Lancet. 359:2002;189-198.
15. Veselka J., Tesar D., Mates M. Coronary stenting without predilatation a clinical routine with Jomed Delivery System Catheter . Cardiovasc Interv. 46:1999;121-122.
16. Gulba D.C., Tanswell P., Dechend R., Sosada M., Weis A., Waigand J., Uhlich F., Hauck S., Jost S., Rafflenbeul W., Lichtlen P.R., Dietz R. Six-minute alteplase protocol a new accelerated recombinant tissue-type plasminogen activator regimen for thrombolysis in acute myocardial infarction . J Am Coll Cardiol. 30:1997;1611-1617.
17. Gibson C.M., Cannon C.P., Murphy S.A., Marble S.J., Barron H.V., Braunwald E. Relationship of the TIMI myocardial perfusion grades, flow grades, frame count, and percutaneous coronary intervention to long-term outcomes after thrombolytic administration in acute myocardial infarction. Circulation. 105:2002;1909-1913.
18. Gibson C.M., Cannon C.P., Murphy S.A., Ryan K.A., Mesley R., Marble S.J., McCabe S.H., Van de Werf F., Braunwald E. Relationship of TIMI myocardial perfusion grade to mortality after administration of thrombolytic drugs. Circulation. 101:2000;125-130.
19. Bailar J.C. III, Mosteller F. Medical Uses of Statistics. 2nd Ed:1992;NEJM Books, Waltham, MA. 261-269; 281-291.
20. Cox D.R. Regression models and life-tables. J R Stat Soc [B]. 34:1972;187-220.
21. Fergusson D., Aaron S.D., Guyatt G., Hebert P. Post-randomization exclusions the intention to treat principle and excluding patients from analysis . BMJ. 325:2002;652-654.
22. Giugliano R.P., Roe M.T., Harrington R.A., Gibson C.M., Zeymer U., Van de Werf F., Baran K.W., Hobbach H.P., Woodlief L.H., Hannan K.L., et al. Combination reperfusion therapy with eptifibatide and reduced-dose tenecteplase for ST-elevation myocardial infarction results of the Integrilin and Tenecteplase in acute myocardial infarction (INTEGRITI) Phase II Angiographic Trial . J Am Coll Cardiol. 41:2003;1251-1260.
23. Armstrong P.W., Collen D., Antman E. Fibrinolysis for acute myocardial infarction the future is here and now . Circulation. 107:2003;2533-2537.
24. Henriques J.P., Zijlstra F., van't Hof A.W., de Boer M.J., Dambrink J.H., Gosselink M., Hoorntje J.C., Suryapranata H. Angiographic assessment of reperfusion in acute myocardial infarction by myocardial blush grade. Circulation. 107:2003;2115-2119.
25. Lincoff AM, Califf RM, Van de Werf F, Willerson JT, White HD, Armstrong PW, Guetta V, Gibler WB, Hochman JS, Bode C, et al, Global Use of Strategies To Open Coronary Arteries Investigators (GUSTO). Mortality at 1 year with combination platelet glycoprotein IIb/IIIa inhibition and reduced-dose fibrinolytic therapy vs conventional fibrinolytic therapy for acute myocardial infarction: GUSTO V randomized trial. JAMA;288:2130-2135.
26. Gersh B.J. Acute myocardial infarction. Results of the ASSENT-3 Trial. Rev Cardiovasc Med. 3:2002;111-115.